LAVA THERAPEUTICS NV (LVTX)

NL0015000AG6 - Common Stock

2.97  0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
5M
42.86%		19.39M
287.80%		6.769M
-65.09%		7.14M
5.48%
EBITDA
YoY % growth
-43.79M
-202.84%		-34.06M
22.22%		-41.975M
-23.24%		-29.055M
30.78%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-44.35M
-197.25%		-34.84M
21.44%		-43.253M
-24.15%		-43.313M
-0.14%
Operating Margin
-887.00%-179.68%-638.99%-606.63%
EPS
YoY % growth
-11.12-1.25
88.76%		-1.59
-27.21%		-1.54
2.92%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.13
75.94%
Revenue
Q2Q % growth		7.14M
485.25%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-5.216M
61.48%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 -0.24
57.89%		-0.13-0.11-88.24%
Q3 2023
Q2Q % growth		 -0.34
-944.72%		-0.500.1631.97%
Q2 2023
Q2Q % growth		 -0.48
-54.92%		-0.480.000.58%
Q1 2023
Q2Q % growth		 -0.53
-29.16%		-0.530.000.08%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 353K
-86.63%		6.375M-6.022M-94.46%
Q3 2023
Q2Q % growth		 53K
-99.65%		53K∞%
Q2 2023
Q2Q % growth		 5.14M
993.62%		849.997K4.29M504.71%
Q1 2023
Q2Q % growth		 1.22M
19.61%		1.22M∞%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS51.92% 70.59% 11.11% 15.61%
Revenue100% N/A N/A N/A